BJP CPD Online e-learning site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunbar, G. C.
Right arrow Articles by Shrivastava, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunbar, G. C.
Right arrow Articles by Shrivastava, R. K.

The British Journal of Psychiatry 159: 394-398 (1991)
© 1991 The Royal College of Psychiatrists

A comparison of paroxetine, imipramine and placebo in depressed out- patients

GC Dunbar, JB Cohn, LF Fabre, JP Feighner, RR Fieve, J Mendels and RK Shrivastava
CNS Therapeutic Unit, Clinical Research and Development, SmithKline Beecham Pharmaceuticals, Long Beach.

To compare the safety and antidepressant efficacy of paroxetine, imipramine, and placebo, data from six centres using the same protocol were pooled. A double-blind parallel-group design was used, with therapy lasting six weeks. From week 2 onwards, both the 240 paroxetine- treated and the 237 imipramine-treated patients were significantly different from the 240 placebo-treated patients, but no different from each other. Side-effects with paroxetine were less likely to lead to drop-out than with imipramine. Paroxetine had a possible earlier antidepressant effect than imipramine, and a possible earlier beneficial effect on anxiety symptoms associated with depression.


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
G. Gartlehner, B. N. Gaynes, R. A. Hansen, P. Thieda, A. DeVeaugh-Geiss, E. E. Krebs, C. G. Moore, L. Morgan, and K. N. Lohr
Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians
Ann Intern Med, November 18, 2008; 149(10): 734 - 750.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
J. G. Edwards
Newer v. older antidepressants in long-term pharmacotherapy: REVISITING... PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
Advan. Psychiatr. Treat., May 1, 2005; 11(3): 184 - 194.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
P. Stolk, M. J ten Berg, M. E. Hemels, and T. R Einarson
Meta-Analysis of Placebo Rates in Major Depressive Disorder Trials
Ann. Pharmacother., December 1, 2003; 37(12): 1891 - 1899.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
H. Melander, J. Ahlqvist-Rastad, G. Meijer, and B. Beermann
Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
BMJ, May 29, 2003; 326(7400): 1171 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
S. Garattini, V. Bertele, and L. L. Bassi
How can research ethics committees protect patients better?
BMJ, May 29, 2003; 326(7400): 1199 - 1201.
[Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
M. Zimmerman, J. I. Mattia, and M. A. Posternak
Are Subjects in Pharmacological Treatment Trials of Depression Representative of Patients in Routine Clinical Practice?
Am J Psychiatry, March 1, 2002; 159(3): 469 - 473.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
M. A. Posternak, M. Zimmerman, G. I. Keitner, and I. W. Miller
A Reevaluation of the Exclusion Criteria Used in Antidepressant Efficacy Trials
Am J Psychiatry, February 1, 2002; 159(2): 191 - 200.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
C. B. Nemeroff, D. L. Evans, L. Gyulai, G. S. Sachs, C. L. Bowden, I. P. Gergel, R. Oakes, and C. D. Pitts
Double-Blind, Placebo-Controlled Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression
Am J Psychiatry, June 1, 2001; 158(6): 906 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Arch Fam MedHome page
K. DasGupta
Treatment of Depression in Elderly Patients: Recent Advances
Arch Fam Med, June 1, 1998; 7(3): 274 - 280.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
I M Anderson and B M Tomenson
Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis
BMJ, June 3, 1995; 310(6992): 1433 - 1438.
[Abstract] [Full Text]

Home page
 BMJHome page
G Harrison
Controversies in Management: New or old antidepressants? New is better
BMJ, November 12, 1994; 309(6964): 1280 - 1281.
[Full Text]

Home page
 J PsychopharmacolHome page
I.M. Anderson and B.M. Tomenson
The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants
J Psychopharmacol, January 1, 1994; 8(4): 238 - 249.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1991 The Royal College of Psychiatrists.